Mizuho upgraded shares of Horizon Pharma (NASDAQ:HZNP) from a neutral rating to a buy rating in a research report report published on Friday, MarketBeat.com reports. The firm currently has $18.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $12.00.

Several other research firms have also weighed in on HZNP. Zacks Investment Research lowered shares of Horizon Pharma from a hold rating to a sell rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma and gave the company a buy rating in a research report on Sunday, October 15th. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the company a buy rating in a research report on Friday, December 1st. Jefferies Group increased their price target on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a buy rating in a research report on Tuesday, November 7th. Finally, ValuEngine lowered shares of Horizon Pharma from a buy rating to a hold rating in a research report on Sunday, December 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $19.25.

Horizon Pharma (NASDAQ HZNP) traded up $0.09 on Friday, reaching $15.18. 3,326,022 shares of the company traded hands, compared to its average volume of 1,834,567. The company has a market capitalization of $2,490.00, a price-to-earnings ratio of -4.99, a P/E/G ratio of 0.71 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. Horizon Pharma has a one year low of $9.45 and a one year high of $17.69.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The company had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share. equities analysts predict that Horizon Pharma will post 0.72 EPS for the current year.

A number of large investors have recently modified their holdings of HZNP. Bank of New York Mellon Corp boosted its position in Horizon Pharma by 19.7% during the second quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock worth $10,866,000 after purchasing an additional 150,850 shares during the period. Legal & General Group Plc boosted its position in Horizon Pharma by 4.2% during the second quarter. Legal & General Group Plc now owns 56,552 shares of the biopharmaceutical company’s stock worth $669,000 after purchasing an additional 2,282 shares during the period. Prudential Financial Inc. boosted its position in Horizon Pharma by 5.0% during the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 830 shares during the period. Swiss National Bank boosted its position in Horizon Pharma by 13.1% during the second quarter. Swiss National Bank now owns 270,356 shares of the biopharmaceutical company’s stock worth $3,209,000 after purchasing an additional 31,300 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Horizon Pharma during the second quarter worth about $523,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Horizon Pharma (HZNP) Rating Increased to Buy at Mizuho” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/15/horizon-pharma-hznp-rating-increased-to-buy-at-mizuho.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related stocks with our FREE daily email newsletter.